The safety and efficacy profile of RAD001 has not yet been established in oncology and there is no guarantee that RAD001 will become commercially available for oncology indications. The active ingredient in RAD001 is everolimus, which is available in different dosage strengths under the trade name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the EU in 2003.
In addition to renal cell carcinoma (RCC), RAD001 is being evaluated as a single agent or in combination with existing therapies in neuroendocrine tumors, lymphoma, breast, gastric, lung and other cancers, as well as tuberous sclerosis.
About renal cell carcinoma (RCC)
In the US, kidney cancer accounts for approximately 3% of all adult cancers. RCC, the most common type of kidney cancer, accounts for approximately 90% of malignant kidney tumors. In RCC, cancer cells develop in the lining of the kidney's tubes and grow into a tumor.
The foregoing release contains forward-looking statements that can be
identified by terminology such as "potential", "proposed", "believe",
"should", "priority review", "potentially", "encouraged", "committed",
"may", "suggest", or similar expressions, or by express or implied
discussions regarding potential marketing approvals for RAD001 or regarding
potential future revenues from RAD001. You should not place undue reliance
on these statements. Such forward-looking statements reflect the current
views of the Company regarding future events, and involve known and unknown
risks, uncertainties and other fact
|SOURCE Novartis Pharmaceuticals Corporation|
Copyright©2008 PR Newswire.
All rights reserved